Genprex, Inc. Files 8-K Amid Listing Concerns
Ticker: GNPX · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1595248
Sentiment: bearish
Topics: delisting, listing-rule, regulatory
Related Tickers: GNPX
TL;DR
Genprex 8-K filed, looks like they might be delisted. Big trouble.
AI Summary
Genprex, Inc. filed an 8-K on August 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Austin, Texas.
Why It Matters
This filing indicates potential issues with Genprex, Inc.'s continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to satisfy continued listing rules is a significant negative event that can lead to severe stock price declines and reduced liquidity.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- August 19, 2025 (date) — Date of earliest event reported
- August 20, 2025 (date) — Date of report
- Austin, TX (location) — Principal executive offices location
- 512-537-7997 (phone_number) — Registrant's telephone number
FAQ
What specific listing rule has Genprex, Inc. failed to satisfy?
The filing does not specify the exact listing rule that Genprex, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the exact date of the notice of delisting or failure to satisfy a continued listing rule?
The earliest event reported is August 19, 2025, and the report is dated August 20, 2025.
What is Genprex, Inc.'s primary business according to the SIC code?
Genprex, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are Genprex, Inc.'s principal executive offices located?
Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the Commission File Number for Genprex, Inc.?
The Commission File Number for Genprex, Inc. is 001-38244.
Filing Stats: 1,419 words · 6 min read · ~5 pages · Grade level 17 · Accepted 2025-08-20 16:16:08
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
- $1,391,195 — e the Company's stockholders' equity of $1,391,195 as reported in the Company's Quarterly
- $2.5 m — 2025 was below the required minimum of $2.5 million, and because, as of August 19, 20
- $1.00 m — ny has not regained compliance with the $1.00 minimum bid price requirement set forth i
- $1.00 — ties to maintain a minimum bid price of $1.00 per share and, as previously disclosed,
- $5,000,000 m — ause the Company does not meet Nasdaq's $5,000,000 minimum stockholders' equity initial list
Filing Documents
- gnpx20250818_8k.htm (8-K) — 35KB
- 0001437749-25-027451.txt ( ) — 164KB
- gnpx-20250819.xsd (EX-101.SCH) — 3KB
- gnpx-20250819_def.xml (EX-101.DEF) — 11KB
- gnpx-20250819_lab.xml (EX-101.LAB) — 15KB
- gnpx-20250819_pre.xml (EX-101.PRE) — 11KB
- gnpx20250818_8k_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing . On August 19, 2025, Genprex, Inc. ("Genprex" or the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the "Minimum Stockholders' Equity Requirement"), because the Company's stockholders' equity of $1,391,195 as reported in the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025 was below the required minimum of $2.5 million, and because, as of August 19, 2025, the Company did not meet the alternative compliance standards relating to market value of listed securities or net income from continuing operations. The Staff indicated that this non-compliance with the Minimum Stockholders' Equity Requirement serves as additional and separate basis for delisting the Company's securities from Nasdaq. As previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Bid Price Requirement") and because of the Company's ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company's securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"). The Bid Price Requirement of the Nasdaq Listing Rules requires listed securities to maintain a minimum bid price of $1.00 per share and, as previously disclosed, on February 7, 2025, Nasdaq had notified the Company that based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, th
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: August 20, 2025 By: /s/ Ryan Confer Ryan Confer President, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)